Efficacy and Safety of Guselkumab, an Interleukin ‐23p19‐Specific Monoclonal Antibody, Through 1 Year in Biologic‐naïve Psoriatic Arthritis Patients

ConclusionIn biologic ‐naïve PsA patients, guselkumab provided sustained improvements across diverse manifestations and maintained a favorable benefit‐risk profile through Week52.

Source: Arthritis and Rheumatology - October 11, 2020 Category: Rheumatology Authors: Iain B. McInnes, Proton Rahman, Alice B. Gottlieb, Elizabeth C. Hsia, Alexa P. Kollmeier, Soumya D. Chakravarty, Xie L. Xu, Ramanand A. Subramanian, Prasheen Agarwal, Shihong Sheng, Yusang Jiang, Bei Zhou, Yanli Zhuang, D ésirée van, der Heijde, Phili Tags: FULL LENGTH Source Type: research